Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
about
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia CellsA novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growthHistone deacetylase signaling in cardioprotectionEvolution of the arginase fold and functional diversityEpigenetic control of skull morphogenesis by histone deacetylase 8Histone deacetylase inhibitors: Potential in cancer therapyHistone acetylation: novel target for the treatment of acute lymphoblastic leukemiaMetabolism, longevity and epigeneticsTrials with 'epigenetic' drugs: an updateMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsLysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulationEffectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cellsMolecular Targets and Emerging Therapeutic Options for Uterine LeiomyosarcomaHistone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilizationHigh class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.Epigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancerSpecific activity of class II histone deacetylases in human breast cancer cellsHistone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ ExpressionHR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.A bioluminogenic HDAC activity assay: validation and screening.Histone deacetylases govern cellular mechanisms underlying behavioral and synaptic plasticity in the developing and adult brain.Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.Deacetylation of the DNA-binding domain regulates p53-mediated apoptosisIdentification of small molecule modulators of gene transcription with anticancer activity.Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossLysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition.The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.Selective inhibitors of protein methyltransferasesPolyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage.Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking studyFollow-up of patients with mycosis fungoides after interferon α2b treatment failure.
P2860
Q21328686-985F711C-63BC-4DB3-ADA0-C5998B2101F2Q24309277-290F1FE5-07C0-4AE7-8E66-657FF60432D2Q24568237-A963E35E-FCC3-40AE-AB46-E802EAC1BFA2Q24642568-C8406A44-A1E5-43E3-B3E4-53B1B4E58842Q24646214-A3ED9D6E-F40D-42C6-99E5-FBE026EFCE0FQ24649025-0E53DAF4-01D5-40FC-A562-E76987B0ABD1Q26778780-5D251F47-EC73-4F19-ACA3-281937CD45C4Q26992212-AC8BB731-0385-42FE-B909-C340BB2075F3Q27000542-0DA8C8CA-9FBF-48D1-92DA-C96D5C5F7931Q27015931-395A2B96-7532-4148-B8A5-B85153032774Q27021965-B785CD5C-CEB2-4289-9871-58252996F34EQ27335252-24BF55E8-094E-4CC6-A5E0-BAF1CBEF7B7DQ28076023-95EF8125-D0A4-4248-A837-D0F11E12BD19Q28468630-89CBAF2C-6D15-42AC-A398-4B5602435B83Q30884835-A7FB9031-CF47-438D-A9D6-87AEB6ED10A5Q33476165-C02E3A14-0DA5-411B-86F9-A60D0E554762Q33587441-9B0C2D35-3530-4166-82D7-EEB9D006EE13Q33606021-3DE8F1B4-BA90-4E12-ADB6-D79AB5E611CFQ33705588-83ED23F8-50FA-4BD8-BBC1-FE23939E9F44Q33741142-F91B0845-BC04-40B0-8102-0F65F18CEA3CQ33755131-D8D23602-EBAC-4992-A974-105520C02290Q33778769-84D535F0-DFC3-4765-9A41-BB843F87B7FEQ33829390-99B310FF-5CF6-4853-88C6-43EA59CFF478Q33831060-1F971707-906F-4C96-9D7A-3D76FE4799F1Q33989826-FFA610B3-266D-4715-B4F8-BD5CFD484A5EQ34073214-E71C91BB-80C4-4CC5-8A0C-8B8C1A4E1617Q34093052-33B66BA4-40A7-45BE-B717-0228853B5654Q34101029-19688175-D1FD-474D-B282-A0C99CA5E255Q34383040-7A2334DB-A6D6-4D82-A77A-892F562423E7Q34575823-68DFE9CF-FF9C-4C27-BB37-596DE721491FQ34576203-79BD28B7-FDC2-467B-AB41-CE65A4305A07Q34656429-4B2D3C5D-8C56-4DCF-9057-1DA140A12D2CQ34686787-9AA80543-7322-43D9-83B3-788E1A114314Q34764399-32960C2C-43ED-47AC-9B6D-B183C4D283DAQ34905146-04C5E03B-31A9-46EF-A5F8-D2D0526C2E04Q35060679-3A062A36-FB25-4BBC-BF83-B05FFC2F48C4Q35135783-8ADEA161-DA56-4E64-9838-378C2B9331B5Q35184499-2E0688F7-01D6-4DAC-BA2B-135E4F797146Q35542579-41E38AAA-BDFA-4027-B60B-9F370BB1ECEEQ35620524-B91BEB4D-93F7-43F2-8D75-F42D04021819
P2860
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@ast
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@en
type
label
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@ast
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@en
prefLabel
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@ast
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@en
P2860
P1476
Vorinostat: a new oral histone ...... for cutaneous T-cell lymphoma.
@en
P2093
Madeleine Duvic
P2860
P304
P356
10.1517/13543784.16.7.1111
P407
P577
2007-07-01T00:00:00Z